WID-Easy Somerset Pilot

Location

Somerset NHS foundation Trust Sites

Description

Provision of a full end to end testing service, including sampling kit supply, sample transport, and result reporting.

Total Quantity or Scope

The WID®-easy test is a new, minimally invasive test available in the UK that uses a simple vaginal swab to help detect or rule out the risk of endometrial (womb) cancer in women experiencing abnormal bleeding. It is a far less intrusive procedure, providing faster links to the appropriate clinical pathway. A service evaluation project would aim to test the initial adoption of the WID®-easy test at the Somerset NHS Foundation Trust. The WID®-easy test will be the frontline triage methodology for all women referred to the Trust 45 years or older with AUB and determine the next step in the clinical workflow. This notice is an intention to award a contract under the most suitable provider process. The approximate lifetime value of the contract is £435,000.00. This is a new service with a new provider. The dates between which the services are intended to be provided are between March 2026 and March 2027.

Award Detail

Renewal Options

1 x 12 month extension

Award Criteria

CPV Codes

• 85111300 - Gynaecological hospital services
• 85111800 - Pathology services

Indicators

• Options are available.
• Award on basis of price and quality.

Legal Justification

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by 25 February 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR'.

Other Information

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by 25 February 2026. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.' Representations should be sent: servicesteam.procurement@SomersetFT.nhs.uk Award decision-makers; Cancer Programme Manager. No conflicts or potential conflicts of interest of individuals making the decision were identified. The key criteria were weighted as follows: 30 % Quality and Innovation 20 % Value 20 % Integration, Collaboration and Service Sustainability 20 % Improving access, reducing health inequalities and facilitating choice 10 % Social value Quality and Innovation were weighted highest, with particular emphasis on the potential for earlier diagnosis and improved patient experience being key. Considerable emphasis was also placed on Integration with existing gynaecology and cancer pathways, alongside overall Value, recognising their importance in delivering a coherent, efficient, and sustainable service model. The rationale for choosing the provider with reference to the key criteria: They are uniquely capable of safely delivering the required WID‑easy/WID‑qEC triage testing at scale, and best meet the PSR key criteria of quality, value, integration and social value. Their clinically validated pathway for peri‑ and post‑menopausal women with abnormal uterine bleeding is already in operation, with UK evidence showing substantial reductions in unnecessary hysteroscopies while maintaining cancer detection, thereby improving patient experience and safety and supporting earlier diagnosis ambitions. The provider holds the necessary accredited laboratory infrastructure, high‑throughput capacity and data‑governance arrangements to deliver rapid turnaround times, integrate results into existing gynaecology and cancer pathways, and collaborate with local NHS partners on training, audit and service development, ensuring a proportionate, efficient and sustainable solution that represents best value for the public. They are currently the only provider of this service in the UK.